Abstract
Background and purpose: To compare the course of symptoms and health-related quality-of-life (HRQOL) after immediate thoracic radiotherapy (TRT) between symptomatic (S) and non-symptomatic (NS) patients with advanced NSCLC.
Patients and methods: 407 stage III/IV patients were initially treated with immediate TRT within a randomised phase III trial comparing different fractionation schedules. At inclusion, patients were prospectively stratified according to presence (S) or absence (NS) of tumour-related chest/airway symptoms to facilitate comparison between these groups. The EORTC QLQ-C30 and LC-13 were used for symptom and HRQOL assessments at baseline and at regular intervals up to 1 year (N = 395).
Results: NS patients had significantly more favourable baseline characteristics when compared to S patients with a median survival of 11.8 versus 6.0 months (P < 0.0001), respectively. At baseline, S patients demonstrated HRQOL scores inferior to those of NS patients (P < 0.01) for most scales. Until week 14, NS patients developed more symptoms while S patients experienced symptom relief in most scales. After week 14, no significant differences could be observed between the groups.
Conclusion: This study indicates that immediate TRT, given to patients with minimal/none chest symptoms, does not prevent development of disease-related symptoms and diminished HRQOL. A wait-and-see policy appears to be acceptable. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
| Original language | English |
|---|---|
| Pages (from-to) | 141-148 |
| Number of pages | 8 |
| Journal | Radiotherapy and Oncology |
| Volume | 75 |
| Issue number | 2 |
| Early online date | 11 May 2005 |
| DOIs | |
| Publication status | Published - May 2005 |
Keywords
- palliative radiotherapy
- lung cancer
- NSCLC
- immediate treatment
- quality-of-life
- QUALITY-OF-LIFE
- PALLIATIVE THORACIC RADIOTHERAPY
- QUESTIONNAIRE QLQ-C30
- ASYMPTOMATIC PATIENTS
- INOPERABLE CARCINOMA
- CLINICAL-TRIALS
- SCORES
- YES
- NO
Cite this
Immediate or delayed radiotherapy in advanced non-small-cell lung cancer (NSCLC)? Data from a prospective randomised study. / Sundstrøm, S.; Bremnes, R.; Brunsvig, P.; Aasebø, U.; Klepp, O.; Fayers, Peter; Kaasa, S.; Norwegian Lung Canc Study Grp.
In: Radiotherapy and Oncology, Vol. 75, No. 2, 05.2005, p. 141-148.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Immediate or delayed radiotherapy in advanced non-small-cell lung cancer (NSCLC)? Data from a prospective randomised study.
AU - Sundstrøm, S.
AU - Bremnes, R.
AU - Brunsvig, P.
AU - Aasebø, U.
AU - Klepp, O.
AU - Fayers, Peter
AU - Kaasa, S.
AU - Norwegian Lung Canc Study Grp
N1 - Acknowledgements This study was initiated and performed by The Norwegian Lung Cancer Study Group. The secretarial assistance at the Clinical Research Office, The University Hospital of Trondheim is greatly appreciated
PY - 2005/5
Y1 - 2005/5
N2 - Background and purpose: To compare the course of symptoms and health-related quality-of-life (HRQOL) after immediate thoracic radiotherapy (TRT) between symptomatic (S) and non-symptomatic (NS) patients with advanced NSCLC.Patients and methods: 407 stage III/IV patients were initially treated with immediate TRT within a randomised phase III trial comparing different fractionation schedules. At inclusion, patients were prospectively stratified according to presence (S) or absence (NS) of tumour-related chest/airway symptoms to facilitate comparison between these groups. The EORTC QLQ-C30 and LC-13 were used for symptom and HRQOL assessments at baseline and at regular intervals up to 1 year (N = 395).Results: NS patients had significantly more favourable baseline characteristics when compared to S patients with a median survival of 11.8 versus 6.0 months (P < 0.0001), respectively. At baseline, S patients demonstrated HRQOL scores inferior to those of NS patients (P < 0.01) for most scales. Until week 14, NS patients developed more symptoms while S patients experienced symptom relief in most scales. After week 14, no significant differences could be observed between the groups.Conclusion: This study indicates that immediate TRT, given to patients with minimal/none chest symptoms, does not prevent development of disease-related symptoms and diminished HRQOL. A wait-and-see policy appears to be acceptable. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
AB - Background and purpose: To compare the course of symptoms and health-related quality-of-life (HRQOL) after immediate thoracic radiotherapy (TRT) between symptomatic (S) and non-symptomatic (NS) patients with advanced NSCLC.Patients and methods: 407 stage III/IV patients were initially treated with immediate TRT within a randomised phase III trial comparing different fractionation schedules. At inclusion, patients were prospectively stratified according to presence (S) or absence (NS) of tumour-related chest/airway symptoms to facilitate comparison between these groups. The EORTC QLQ-C30 and LC-13 were used for symptom and HRQOL assessments at baseline and at regular intervals up to 1 year (N = 395).Results: NS patients had significantly more favourable baseline characteristics when compared to S patients with a median survival of 11.8 versus 6.0 months (P < 0.0001), respectively. At baseline, S patients demonstrated HRQOL scores inferior to those of NS patients (P < 0.01) for most scales. Until week 14, NS patients developed more symptoms while S patients experienced symptom relief in most scales. After week 14, no significant differences could be observed between the groups.Conclusion: This study indicates that immediate TRT, given to patients with minimal/none chest symptoms, does not prevent development of disease-related symptoms and diminished HRQOL. A wait-and-see policy appears to be acceptable. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
KW - palliative radiotherapy
KW - lung cancer
KW - NSCLC
KW - immediate treatment
KW - quality-of-life
KW - QUALITY-OF-LIFE
KW - PALLIATIVE THORACIC RADIOTHERAPY
KW - QUESTIONNAIRE QLQ-C30
KW - ASYMPTOMATIC PATIENTS
KW - INOPERABLE CARCINOMA
KW - CLINICAL-TRIALS
KW - SCORES
KW - YES
KW - NO
U2 - 10.1016/j.radonc.2005.03.028
DO - 10.1016/j.radonc.2005.03.028
M3 - Article
VL - 75
SP - 141
EP - 148
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
SN - 0167-8140
IS - 2
ER -